Central Trust Company’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.4K | Hold |
112
| – | – | ﹤0.01% | 989 |
|
|
2025
Q4 | $21.2K | Buy |
112
+8
| +8% | +$1.54K | ﹤0.01% | 970 |
|
|
2025
Q3 | $18.4K | Sell |
104
-62
| -37% | -$9.22K | ﹤0.01% | 1004 |
|
|
2025
Q2 | $18.9K | Hold |
166
| – | – | ﹤0.01% | 996 |
|
|
2025
Q1 | $17.5K | Hold |
166
| – | – | ﹤0.01% | 997 |
|
|
2024
Q4 | $17.8K | Buy |
166
+131
| +374% | +$14.8K | ﹤0.01% | 989 |
|
|
2024
Q3 | $3.5K | Hold |
35
| – | – | ﹤0.01% | 1202 |
|
|
2024
Q2 | $2.95K | Hold |
35
| – | – | ﹤0.01% | 1237 |
|
|
2024
Q1 | $2.56K | Hold |
35
| – | – | ﹤0.01% | 1251 |
|
|
2023
Q4 | $2.5K | Hold |
35
| – | – | ﹤0.01% | 1263 |
|
|
2023
Q3 | $2.1K | Hold |
35
| – | – | ﹤0.01% | 1257 |
|
|
2023
Q2 | $2.52K | Hold |
35
| – | – | ﹤0.01% | 1160 |
|
|
2023
Q1 | $2.58K | Hold |
35
| – | – | ﹤0.01% | 1176 |
|
|
2022
Q4 | $2.34K | Sell |
35
-21
| -38% | -$1.36K | ﹤0.01% | 1145 |
|
|
2022
Q3 | $3K | Hold |
56
| – | – | ﹤0.01% | 1159 |
|
|
2022
Q2 | $3K | Hold |
56
| – | – | ﹤0.01% | 1169 |
|
|
2022
Q1 | $4K | Hold |
56
| – | – | ﹤0.01% | 1176 |
|
|
2021
Q4 | $5K | Hold |
56
| – | – | ﹤0.01% | 1134 |
|
|
2021
Q3 | $5K | Hold |
56
| – | – | ﹤0.01% | 1123 |
|
|
2021
Q2 | $5K | Hold |
56
| – | – | ﹤0.01% | 1088 |
|
|
2021
Q1 | $5K | Hold |
56
| – | – | ﹤0.01% | 1013 |
|
|
2020
Q4 | $3K | Sell |
56
-80
| -59% | -$4.56K | ﹤0.01% | 1023 |
|
|
2020
Q3 | $8K | Sell |
136
-37
| -21% | -$2.52K | ﹤0.01% | 886 |
|
|
2020
Q2 | $12K | Hold |
173
| – | – | ﹤0.01% | 813 |
|
|
2020
Q1 | $8K | Buy |
173
+48
| +38% | +$2.72K | ﹤0.01% | 898 |
|
|
2019
Q4 | $8K | Sell |
125
-11
| -8% | -$735 | ﹤0.01% | 981 |
|
|
2019
Q3 | $8K | Sell |
136
-34
| -20% | -$2.13K | ﹤0.01% | 941 |
|
|
2019
Q2 | $12K | Hold |
170
| – | – | ﹤0.01% | 889 |
|
|
2019
Q1 | $13K | Buy |
170
+11
| +7% | +$833 | ﹤0.01% | 839 |
|
|
2018
Q4 | $13K | Hold |
159
| – | – | ﹤0.01% | 843 |
|
|
2018
Q3 | $27K | Sell |
159
-45
| -22% | -$6.78K | ﹤0.01% | 790 |
|
|
2018
Q2 | $26K | Buy |
204
+16
| +9% | +$1.78K | ﹤0.01% | 775 |
|
|
2018
Q1 | $19K | Sell |
188
-150
| -44% | -$14.8K | ﹤0.01% | 847 |
|
|
2017
Q4 | $29K | Hold |
338
| – | – | ﹤0.01% | 795 |
|
|
2017
Q3 | $29K | Hold |
338
| – | – | ﹤0.01% | 774 |
|
|
2017
Q2 | $26K | Sell |
338
-388
| -53% | -$27.1K | ﹤0.01% | 801 |
|
|
2017
Q1 | $48K | Buy |
726
+13
| +2% | +$855 | ﹤0.01% | 734 |
|
|
2016
Q4 | $45K | Sell |
713
-95
| -12% | -$6K | ﹤0.01% | 728 |
|
|
2016
Q3 | $51K | Buy |
808
+5
| +0.6% | +$367 | ﹤0.01% | 672 |
|
|
2016
Q2 | $60K | Sell |
803
-7
| -0.9% | -$519 | ﹤0.01% | 628 |
|
|
2016
Q1 | $54K | Buy |
810
+65
| +9% | +$3.95K | ﹤0.01% | 654 |
|
|
2015
Q4 | $50K | Buy |
745
+306
| +70% | +$18.9K | ﹤0.01% | 646 |
|
|
2015
Q3 | $23K | Sell |
439
-55
| -11% | -$3.34K | ﹤0.01% | 796 |
|
|
2015
Q2 | $31K | Buy |
494
+50
| +11% | +$2.73K | ﹤0.01% | 768 |
|
|
2015
Q1 | $21K | Hold |
444
| – | – | ﹤0.01% | 810 |
|
|
2014
Q4 | $15K | Sell |
444
-29
| -6% | -$943 | ﹤0.01% | 902 |
|
|
2014
Q3 | $14K | Buy |
473
+417
| +745% | +$13.8K | ﹤0.01% | 925 |
|
|
2014
Q2 | $2K | Hold |
56
| – | – | ﹤0.01% | 1130 |
|
|
2014
Q1 | $2K | Hold |
56
| – | – | ﹤0.01% | 1144 |
|
|
2013
Q4 | $2K | Hold |
56
| – | – | ﹤0.01% | 1094 |
|
|
2013
Q3 | $2K | Hold |
56
| – | – | ﹤0.01% | 1113 |
|
|
2013
Q2 | $1K | Buy |
+56
| New | +$1.01K | ﹤0.01% | 1079 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Central Trust Company's LGND Position: Q1 2026 in Review
Central Trust Company held its Ligand Pharmaceuticals (LGND) position steady in Q1 2026 at 112 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #989.
Central Trust Company first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $60K in Q2 2016. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Central Trust Company held 112 shares of Ligand Pharmaceuticals worth $22.4K as of Q1 2026.
- Central Trust Company left its Ligand Pharmaceuticals share count unchanged in Q1 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of Central Trust Company's portfolio in Q1 2026, its #989 holding.
- Central Trust Company first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Central Trust Company's Ligand Pharmaceuticals position peaked at $60K in Q2 2016.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.